Bayer will invest R $ 152 million in Brazil in 2013

SAO PAULO-the Executive Marijn Dekkers, President of Bayer, said that the multinational has important releases for 2013 in the pharmaceutical area in the country and in the world, with a vast "pipeline" (under development) in innovative medicines.
Marijn Dekkers, President of Bayer global
With great participation in the area of agribusiness in Brazil, the current high prices of commodities help lift the company's sales expectation in Cropscience (agribusiness), since the quotations in elevation stimulate the increased acreage for grain, like soybeans and corn, in Brazil.
For this year, the company plans investments of r $ 152 million in Brazil. In addition to the drug Division, the contributions will also be used for chemical and agricultural business (pesticides and seeds), important areas of activity of the company in the country.
In 2012, the Group's billing was r $ 5.7 billion in the country, high of 26% as compared to the same previous period. The expectation for this year is to keep the rate of growth up to two digits.
The Brazil is the fifth largest market in the world and the largest in Latin America. Last year, overall revenue was 39.76 billion euros. In the first quarter of 2013, the global revenue of the Group was 10.3 billion euros, up 3.7% as compared to the same period last year.
If overall health and pharmaceutical segments ("health care") represent the largest share of its sales in Brazil is the opposite. Of the $ 5.7 billion, 29% is farma. Cropscience Division is with 56%.
Marijn Dekkers said that both areas will continue pulling the Group sales in Brazil. "They are two very comparable because areas involve scientists who develop molecules, both to plants and human health. Are two profitable segments for the group, "he said.
The company does not rule out making acquisitions in the country in Cropscience (agribusiness). Dekkers said he predicts growth above two digits for years in Bayer's sales in Brazil.
"The global economic crisis has hit many groups in the world. In Europe is still a challenge. In the us, we are looking at a market recovery. The emerging countries have great potential for expansion, "said Dekkers.
In agriculture, the Group operates with the sale of pesticides and seeds. He believes that the country's agricultural potential is greater for expansion for Bayer than in the USA, for example, a giant market for agriculture. However, according to Dekkers, the American market is more established than in Brazil.
For the Executive, the areas of pesticides and seeds have the same growth potential for Bayer in Brazil.
Acquisitions
The President of Brayer Brazil, Theo Van der Loo said that analyzes opportunities for acquisitions in the pharmaceutical segment. However, according to the Executive, there is ongoing negotiation at the moment. "Depends on the assets, values, portfolio [of drugs]. All of this is evaluated, "he said.
According to him, the area of Cropscience may have a growth greater than the general advancement of Bayer in the country this year, around 10%, in comparison with 2012.
In the chemical segment, in which Bayer also acts, Loo said that recent Government measures of tax exemption should help stimulate investments in this segment. "We suffered strong competition from products imported from China," he said.
To Marijn Dekkers, the company's global President, Brazil has conditions in a few years to become the fourth largest market of the multinational in the world. Currently, the country is the fifth largest market. "Earlier today we were making projections about it and realize that the country has the potential to grow," he said.